Physician profile
Macie Finkelstein
NPI 1114959640
$2,822.52
in general payments reported to CMS, 2019-2025
16 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $29.17 · 2021: $57.35 · 2022: $399 · 2023: $394 · 2024: $591 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.10 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $403.87 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $317.06 | 2021-2025 | Rocklatan, Eysuvis, Tryptyr |
| Horizon Therapeutics Plc | $296.71 | 2022-2023 | Tepezza |
| Genentech USA, INC. | $234.26 | 2019 | |
| Dompe US, INC. | $202.99 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $198.46 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $192.14 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Amgen INC. | $169.73 | 2019-2025 | Tepezza |
| Oyster Point Pharma, INC. | $90.41 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $60.80 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $49.92 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $36.40 | 2022 | |
| Allergan, INC. | $32.45 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $27.70 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $22.52 | 2024 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macie Finkelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.